Heterogeneity of response to imatinib-mesylate (Glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis

Pellegrino Musto, Antonietta Falcone, Grazia Sanpaolo, Carlo Bodenizza, Gianni Perla, Maria Marta Minervini, Nicola Cascavilla, Matteo Dell' Olio, Antonio La Sala, Saverio Mantuano, Lorella Melillo, Michelle Nobile, Potito Rosario Scalzulli, Michele Bisceglia, Angelo Michele Carella

Research output: Contribution to journalArticle

Abstract

Four cases of hypereosinophilic syndrome (HES) treated with the tyrosine-kinase inhibitor imatinibmesylate are reported. The drug was effective in three patients, but a prolonged clinical and hematological remission was obtained only in one patient, due to appearance of resistance or poor tolerability in the other cases. The dose of imatinib necessary to achieve a response ranged from 100 to 600 mg/d. One patient with evidence of a clonal T-cell population did not respond at all. We confirm the efficacy of imatinib in HES, but we also underline that type and duration of response may be variable. This could be due to different pathogenetic mechanisms of the disease in single patients.

Original languageEnglish
Pages (from-to)1219-1222
Number of pages4
JournalLeukemia and Lymphoma
Volume45
Issue number6
DOIs
Publication statusPublished - Jun 2004

Keywords

  • Glivec
  • HES
  • Hypereosinophilic syndrome
  • Imatinib
  • PDGFRA
  • Tyrosine kinase

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Heterogeneity of response to imatinib-mesylate (Glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis'. Together they form a unique fingerprint.

  • Cite this